Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.48 |
| ▸ | NPY4R | P50391 | 13/20 | 0.46 |
| ▸ | NPY1R | P25929 | 8/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.46 |
| ▸ | NPY2R | P49146 | 5/20 | 0.46 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20951500 | 1.00 | SIRT5 (0.48) | SIRT5NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL20952281 | 0.96 | NPY4R (0.47) | SIRT5NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL20952279 | 0.96 | NPY4R (0.47) | SIRT5NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL20951921 | 0.90 | CAPN9 (0.39) | SIRT5NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL20951920 | 0.90 | CAPN9 (0.39) | SIRT5NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL20951230 | 0.87 | SIRT5 (0.58) | SIRT5NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL20951232 | 0.87 | SIRT5 (0.58) | SIRT5NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL20951350 | 0.87 | KISS1R (0.45) | SIRT5NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL20951340 | 0.86 | NPY4R (0.51) | SIRT5NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL20951342 | 0.86 | NPY4R (0.51) | SIRT5NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046729-B2 | Dipeptide analogs as TGF-beta inhibitors | SOUTHERN RESEARCH INSTITUTE (US) | 2021-06-29 | — | — | US | disclosed |
| EP-3700545-A1 | DIPEPTIDE ANALOGS AS TGF-BETA INHIBITORS | Southern Research Institute (US) | 2020-09-02 | — | — | EP | disclosed |
| US-20190127420-A1 | DIPEPTIDE ANALOGS AS TGF-BETA INHIBITORS | UAB RESEARCH FOUNDATION | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127420-A1 | DIPEPTIDE ANALOGS AS TGF-BETA INHIBITORS | TGFB1, TGFB2, SMAD3 | SIRT5 2054/4885NPY4R 3053/4885NPY1R 3152/4885 |
| US-11046729-B2 | Dipeptide analogs as TGF-beta inhibitors | TGFB1, TGFB2, SMAD3 | SIRT5 2054/4885NPY4R 3053/4885NPY1R 3152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.